Loading organizations...
Cenova Capital operates as a healthcare-dedicated investment fund in China, specializing in private healthcare services and digital health. The firm strategically deploys capital to foster innovation and efficiency, actively supporting the market-oriented transformation of China's healthcare sector. It guides portfolio companies through critical growth phases with deep industry expertise.
Dr. Jun WU founded Cenova Capital in 2010, identifying China's need for a more efficient, market-driven healthcare system beyond its traditional state-owned model. This insight led to establishing one of the region's earliest specialized healthcare funds, effectively bridging medical innovation with sophisticated capital market strategies.
Cenova Capital supports portfolio companies and industry leaders with financial investment and strategic oversight. Its investor base includes significant domestic and international institutional entities like sovereign wealth funds and multinational corporations. The firm's vision is to lead China's life science investments, fostering a robust, dynamic healthcare ecosystem.
Key people at Cenova Capital.
Cenova Capital was founded in 2010 by Walter Lau (Co-Founder and Managing Partner) and Jun Wu (Founder and Chairman).
Cenova Capital was founded in 2010 by Walter Lau (Co-Founder and Managing Partner) and Jun Wu (Founder and Chairman).
Key people at Cenova Capital.
Cenova Capital has 4 tracked investments across 4 companies. The latest tracked deal is $40.0M Series B in Eluminex Biosciences in February 2023.
| Date | Company | Round | Lead Investor(s) | Co-Investor(s) |
|---|---|---|---|---|
| Feb 28, 2023 | Eluminex Biosciences | $40.0M Series B | Cenova Capital | 3E Bioventures Capital, Oriza Holdings |
| Apr 1, 2022 | ENSEM Therapeutics | $67.0M Series A | Joshua WU | Granite Asia, Sean CAO, Mitsui & CO. Global Investment, Pavilion Capital |
| Dec 14, 2021 | AnHeart Therapeutics | $61.0M Series B | Ting JIA (tj) | Innovent Biologics, Laurion Capital Management, Sage Partners |
| Dec 8, 2015 | ASLAN Pharmaceuticals | $34.0M Series C | Accuron Technologies | Bioveda Ventures, Haitong International, Morningside, Sagamore Bioventures, Tianda Pharmaceuticals |
